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Background: Previously, we identified three loci affecting HDL-cholesterol levels in a screen for ENU-induced mutations
in mice and discovered two mutated genes. We sought to identify the third mutated gene and further characterize the
mouse phenotype.
Methods: We engaged, DNA sequencing, gene expression profiling, western blotting, lipoprotein characterization,
metabolomics assessment, histology and electron microscopy in mouse tissues.
Results: We identify the third gene as Ampd2, a liver isoform of AMP Deaminase (Ampd), a central component of energy
and purine metabolism pathways. The causative mutation was a guanine-to-thymine transversion resulting in an A341S
conversion in Ampd2. Ampd2 homozygous mutant mice exhibit a labile hypercholesterolemia phenotype,
peaking around 9 weeks of age (251 mg/dL vs. wildtype control at 138 mg/dL), and was evidenced by marked
increases in HDL, VLDL and LDL. In an attempt to determine the molecular connection between Ampd2
dysfunction and hypercholesterolemia, we analyzed hepatic gene expression and found the downregulation of
Ldlr, Hmgcs and Insig1 and upregulation of Cyp7A1 genes. Metabolomic analysis confirmed an increase in hepatic
AMP levels and a decrease in allantoin levels consistent with Ampd2 deficiency, and increases in campesterol and
β-sitosterol. Additionally, nephrotic syndrome was observed in the mutant mice, through proteinuria, kidney
histology and effacement and blebbing of podocyte foot processes by electron microscopy.
Conclusion: In summary we describe the discovery of a novel genetic mouse model of combined transient
nephrotic syndrome and hypercholesterolemia, resembling the human disorder.
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Hypercholesterolemia is a major risk factor for develop-
ing coronary artery disease, the most common cause for
heart disease and the leading cause of death worldwide.
Coronary artery disease occurs when excess cholesterol
in the bloodstream accumulates and forms plaques in
the coronary arteries. This narrowing and hardening of
the arteries can eventually lead to myocardial infarction.
Inherited forms of hypercholesterolemia are present with* Correspondence: dlloyd@amgen.com
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article, unless otherwise stated.very high circulating cholesterol levels. The most com-
mon type of inherited hypercholesterolemia is familial
hypercholesterolemia, which occurs in roughly 1 in 500
people [1]. Known genes related to hypercholesterolemia
include low density lipoprotein receptor (LDLR) [2], pro-
protein convertase subtilisin/kexin type 9 (PCSK9) [3],
apolipoprotein B (APOB) [4] and low density lipoprotein
receptor adaptor protein 1 (LDLRAP1) [5], among
others.
A useful tool for discovering other causative genes in-
volved in hypercholesterolemia is mouse genetics. Quan-
titative trait loci (QTL) analysis has been used to study
the genetics of HDL-cholesterol (HDL-C) levels intral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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as those using the highly potent mutagen N-ethyl-N-
nitrosourea (ENU) have revealed novel genes and biology
[7]. Specifically, genes associated with low HDL-C levels
have been found by utilizing ENU [8], as well as genes as-
sociated with reduced cholesterol and triglyceride levels
[9]. One advantage of ENU screens is that they induce
point mutations, thereby allowing the identification of a
single candidate gene responsible for the phenotype of
interest. ENU screens can also generate an allelic series of
mutations that display a range of effects from complete or
partial loss of function to exaggerated function, and reveal
gene functions in an unbiased manner [10]. We previously
performed an ENU screen to identify lines of mice with al-
tered lipid profiles [11]. One line of mice presented
undetectable levels of HDL-C, caused by a missense muta-
tion in the ATP binding cassette transporter A1 (Abca1)
gene. The second line of mice which had very high levels
of plasma total cholesterol and HDL-C was mapped to a
missense mutation in CCAAT/enhancer binding protein α
(C/ebpα). A third line of mice was characterized with a re-
duced penetrance labile hypercholesterolemia phenotype
but the underlying mutation had not been identified.
In this study, we identify the mutation as a recessive loss
of function missense mutation in the gene encoding ad-
enosine monophosphate deaminase 2 (Ampd2). AMPD is
the rate-limiting enzyme in the catabolism of adenosine
monophosphate (AMP) to uric acid, for the elimination of
nitrogenous waste [12]. It is also a component of the pur-
ine nucleotide cycle, responsible for the deamination of
AMP to inosine monophosphate (IMP), which serves to
replenish intermediates in the tricarboxylic (TCA) cycle
when energy demands are high. In humans, there are at
least four isoforms of AMPD. AMPD1 is the predominant
form in skeletal muscle, AMPD2 is widely expressed in
non-skeletal tissues, especially the liver, and AMPD3 is
found in erythrocytes and is comprised of two isoforms,
E1 and E2 [13].
We now complete the physical mapping and define
the remaining causative mutation in our hypercholester-
olemia mice [11]. We further characterize the Ampd2
mutant mice as having a transient hypercholesterolemia
phenotype that also present with transient nephrotic
syndrome (NS). Upon further investigation we find that
the dyslipidemia noted in these mice parallels the protein-
uria observed and thus represents a novel genetic mouse
model of transient NS accompanied with the lipid abnor-
malities as characterized in the human disease.
Results
Identification of a mutation in Ampd2
We previously reported [11] the mapping of the muta-
tion for the hypercholesterolemic mice to a 7 Mb region
on chromosome 3, with 131 possible candidate genesidentified. Forty five were selected for further mutation
analysis based on functional relevance. After examining
the exons and intronic junctions of these 45 candidate
genes by direct sequencing, we identified a guanine-to-
thymine transversion resulting in an alanine to serine
conversion at amino acid 341 in Ampd2 (Figure 1A).
Using exon capture and high-throughput sequencing we
analyzed the region from D3Mit102 to rs13477320 in 2 af-
fected animals, three ENU mutations were identified: the
A341S missense mutation in Ampd2, and intronic muta-
tions in Magi3 and Slc6a17 (data not shown). Western
blotting illustrated the functional consequence of this mu-
tation on Ampd2 protein expression. Complete loss of
Ampd2 protein was observed in the livers of homozygous
mutant mice (Ampd2m/m), with partial loss evident in the
heterozygous mice (Ampd2+/m) relative to wild-type (+/+)
(Figure 1B). Alanine 341 was conserved in all animal spe-
cies including Caenorhabditis elegans, but not in plants
and fungi (Figure 1C), yet was restricted to a highly con-
served region of the protein.
Lipid characterization of Ampd2 mice
Lipid parameters were analyzed on Ampd2+/+, Ampd2+/m
and Ampd2m/m mice at 9 weeks of age (Figure 2). This
time point was chosen after the observation was made that
these phenotypes were transient in subsequent mouse
plasma collections at 9, 11 and 13 weeks [11] and con-
firmed the previously reported elevated total cholesterol
levels in Ampd2m/m animals (Figure 2A). Additionally
Ampd2m/m mice exhibited reduced penetrance, as evi-
denced by the appearance of some Ampd2m/m mice with
normal total cholesterol levels (Figure 2A). Levels of
HDL-C were also significantly elevated in Ampd2m/m mice
(Figure 2B), mirroring the total cholesterol values for indi-
vidual mice. No differences in triglyceride levels between
Ampd2+/+, Ampd2+/m and Ampd2m/m mice were observed
(Figure 2C). Analysis of ApoA1, the major protein compo-
nent of HDL in plasma, showed a significant elevation in
Ampd2m/m compared to Ampd2+/+ mice (Figure 2D) sup-
porting the HDL-C data. Levels of ApoE were also signifi-
cantly elevated in Ampd2m/m compared to Ampd2+/+ mice
(Figure 2E). The elevation of ApoA1 and ApoE in
Ampd2m/m mice was further evidenced by FPLC analysis
of plasma lipoproteins (Figure 2F). As expected Ampd2m/m
mice were found to have elevated HDL-C levels, in
addition very low-density lipoprotein (VLDL) and low
density lipoprotein (LDL) levels were increased relative to
Ampd2+/+ mice.
Hepatic gene expression analysis of Ampd2 mice
In an attempt to uncover a pathogenic mechanism for the
observed hypercholesterolemia we focused our attention
on liver lipid metabolism. An array of lipid metabolism











































































Figure 2 Lipid parameters of Ampd2m/m, Ampd2+/m and Ampd2+/+ mice. Plasma total cholesterol (A), HDL-C (B), triglyceride (C), ApoA1 (D),
ApoE (E) levels and FPLC lipoprotein analysis (F) of 9-week old mice. Individual mouse values are shown with means ± SEM. Statistical analyses
were carried out by one-way ANOVA using a Tukey post test for panels A, B and C and by unpaired two-tailed t-tests for panels D and E;




Figure 1 Identification of a loss-of-function mutation in Ampd2 in hypercholesterolemic mice. A) Sequencing chromatographs of Ampd2
in Ampd2+/+, Ampd2+/m and Ampd2m/m mice. B) Liver immunoblot analysis of Ampd2 protein in Ampd2+/+, Ampd2+/m and Ampd2m/m mice.
C) Amino acid conservation of mouse Ampd2 residues 321–361 to Ampd2+, mouse Ampd1, mouse Ampd3, rat Ampd2, human Ampd2, dog
Ampd2, Caenorhabditis elegans Ampd, Arabidopsis thaliana AMPD and Saccharomyces cerevisiae Ampd. Arrow indicates residue 341.
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(Figure 3A). Ldlr mRNA was decreased by 36%, which
translated to reduced protein levels of Ldlr (Figure 3B),
consistent with elevated LDL cholesterol levels (Figure 2F).
Transcript levels of 3-hydroxy-3-methylglutaryl-CoA syn-
thase (Hmgcs) were also 47% lower. The cholesterol and
bile acid synthesis enzyme cholesterol 7 alpha-hydroxylase
(Cyp7a1) mRNA was increased by 55% in Ampd2m/m
mice. Insulin-induced gene 1 (Insig1) was decreased by
56% in Ampd2m/m mice. We confirmed normal expression
of Ampd2, indicating the mutation had no effect on
mRNA stability, whereas it likely resulted in protein in-
stability (Figure 1B). We also confirmed normal expres-
sion of the broadly expressed paralog Ampd3, suggesting
no overlapping compensation. In general it appeared that
the changes in gene expression were a consequence of
high cholesterol levels, and not causative, prompting us to
employ additional technologies.
Metabolomic analysis of Ampd2 deficient mice
We engaged metabolomics to assist in determining the
mechanism of hypercholesterolemia in Ampd2m/m mice.
Liver and plasma from 9-week old Ampd2+/+ and
Ampd2m/m mice were collected for metabolite analysis.
These analyses confirmed the cholesterol phenotype of
the Ampd2m/m mice in both plasma and liver samples
(Additional file 1: Table S1). Additionally cholesterol esters
were elevated up to 5 fold. Allantoin, the terminal metab-





Figure 3 Gene expression analysis of Ampd2m/m and Ampd2+/+ mice.
of lipid metabolism genes on fed 9-week old Ampd2+/+ and Ampd2m/m mi
t-tests; * p <0.05 vs. Ampd2+/+. B) Liver immunoblot analysis of Ldlr proteinreduced in the livers from Ampd2m/m mice (Additional
file 1: Table S1). The upstream metabolites AMP and
ATP were significantly increased in Ampd2m/m mice
(Additional file 1: Table S1 and Figure 4). Metabolomic
analysis also demonstrated significant increases in plasma
plant sterols including campesterol and β-sitosterol.
Comparison of Ampd2 deficiency on different genetic
backgrounds
Initial gene mapping was carried out by outcrossing the
ENU harboring C57BL/6 J (B6) genome to C3.SW-H2b/
SnJ (C3) mice, and all studies presented to date have been
using mice from heterozygous matings with this mixed
genetic background. A homogeneous genetic background
was achieved by backcrossing the Ampd2m/m mice to in-
bred B6 mice to obtain a pure B6 background. Ampd2+/+
and Ampd2m/m mice on a mixed B6/C3 background were
compared to those on a pure B6 background with a focus
on plasma cholesterol and urinalysis [14]. Ampd2m/m mice
on both backgrounds exhibited dramatically elevated
levels of urinary protein between 7 and 11 weeks of age,
most evident in B6 mice (Figure 5B and 5E) than the
mixed B6/C3 line, and showing significance throughout
the course of the analysis. Hypercholesterolemia was evi-
dent in Ampd2m/m mice on both genetic backgrounds,
with the mixed B6/C3 background showing higher absolute
cholesterol levels, whereas B6 mice exhibited a milder but
less variable phenotype. Additionally, the mixed back-








A) Liver mRNA levels were assessed by quantitative RT-PCR for an array
ce (n = 5). Statistical analyses were carried out by unpaired two-tailed
in Ampd2+/+, Ampd2+/m and Ampd2m/m mice.
Figure 4 Hepatic AMP, ADP, and ATP levels in Ampd2+/+ and
Ampd2m/m mice. Hepatic AMP, ADP, and ATP levels were
determined by HPLC. Open bars represent AMP; solid bars - ADP
and hatched bars - ATP. Statistical analysis was carried out by
unpaired two-tailed t-tests, * p <0.05 vs. Ampd2+/+.
Helmering et al. Lipids in Health and Disease 2014, 13:167 Page 5 of 11
http://www.lipidworld.com/content/13/1/167levels vs. the Ampd2+/+ mice throughout the course of the
study, peaking at 8–10 weeks of age, while the pure B6
Ampd2m/m mice had elevated cholesterol levels relative to
the Ampd2+/+ mice only from 7–9 weeks of age (Figure 5A
and 5D). Consistent with the presence of proteinuria and
NS (see below), both backgrounds of Ampd2m/m mice dis-
played hypoalbuminemia (Figure 5C and 5F), and similarly
to cholesterol levels, albumin levels attained statistical sig-
nificance at a young age for both lines. Together these data
in both genetic backgrounds revealed that the proteinuria
observed temporally coincided with the cholesterol pheno-
types, suggesting interplay between the traits.
Confirmation of nephrotic syndrome in Ampd2m/m mice
To confirm the effect of the A341S mutation in the kid-
neys of Ampd2m/m mice we investigated Ampd2 protein
abundance in both strains and verified that Ampd2 pro-
tein was absent in the liver and kidney of pure B6
Ampd2m/m mice (Figure 6A). NS was verified in
Ampd2m/m mice by kidney histology (Figure 6B). Pro-
teinaceous tubular casts and interstitial nephritis were
observed in Ampd2m/m mice and not Ampd2+/+ mice
(Figure 6B-D). By TEM, glomeruli of selected Ampd2m/m
mice and Ampd2+/+ mice were examined to ascertain any
ultrastructural differences (Figure 7). Glomeruli from
Ampd2m/m mice showed effacement, fusion, and blebbing
of podocyte foot processes, minimal to moderate thick-
ening of the glomerular basement membrane, as well as
denuding with subsequent pseudomembrane formationof the glomerular endothelium. While damage to foot
processes, basal lamina and glomerular endothelium
represents impairment of the glomerular filtration
membrane, the subtle increase in cellularity of the
mesangium, along with a predominant lymphocytic in-
flammatory infiltrate seen in Ampd2m/m mice, further
supports changes secondary to glomerular dysfunction
with ensuing proteinuria.
Effect of a potent AMPD/adenosine deaminase inhibitor
on lipid and renal profiles of normal mice
Deoxycoformycin is a potent, but nonspecific inhibitor
of AMPD/adenosine deaminase and is an approved che-
motherapeutic drug. It dramatically decreases nucleotide
metabolism and affects the cells ability to process DNA
[15]. B6 mice were given a single injection of 10 mg/kg
deoxycoformycin to determine the effect on plasma
cholesterol and urinary protein levels. At 24 hours post
injection, a rise in cholesterol as well as protein urea was
seen in the plasma of deoxycoformycin treated mice
(Additional file 2: Figure S1A and S1B). This data could
suggest a link between dyslipidemia and NS when Ampd
is inhibited, though the possibility that the response was
an acute health reaction cannot be overlooked.
Discussion
In the present study, we identified a mutation in the
Ampd2 gene that leads to NS and hypercholesterolemia.
The combined phenotypes have not previously been re-
ported in Ampd2 knockout mice [14]; minimal change
kidney disease was observed in these mice, and it was
speculated that Ampd2 function was critical for podo-
cyte survival and related to defects in Inosine-5′-mono-
phosphate (IMP). Furthermore, despite dyslipidemia and
minimal change disease being commonly associated in
human NS, our Ampd2m/m mice offer the first descrip-
tion of a mouse model to present both phenotypes. Fur-
ther investigation will be needed to elucidate if these
phenotypes are physiologically connected, or result inde-
pendently from Ampd2 tissue-specific deficiency. To-
wards this end, restoring Ampd2 function in the liver or
kidney of the Ampd2m/m mice could allow dissection of
this relationship.
We identified a transient cholesterol phenotype in
mixed B6/C3 Ampd2m/m mice, and have now confirmed
that the renal phenotype is transient as well, temporally
mirroring the cholesterol levels. In successive genera-
tions of the mixed B6/C3 Ampd2m/m mice we noticed
less severe incidence of hypercholesterolemia and specu-
late that this could be due to the genetic drift of modi-
fier alleles in the mixed B6/C3 background. To address
this hypothesis, we generated pure backgrounds of
Ampd2m/m mice on both B6 and C3 backgrounds. The
pure B6 Ampd2m/m mice do have a penetrant but lesser
A B C
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Figure 5 Temporal hypercholesterolemia and proteinuria in Ampd2m/m mice in mixed B6/C3 and pure B6 genetic background. A and
D) Plasma cholesterol level time course in Ampd2+/+ and Ampd2m/m mice. B and E) Proteinuria level time course in Ampd2+/+ and Ampd2m/m
mice. C and F) Plasma albumin levels time course in Ampd2+/+ and Ampd2m/m mice on a mixed B6/C3 background and pure B6 background









Ampd2 m/mAmpd2 +/+ Ampd2 m/m DC
Figure 6 Ampd2 deficiency and histological features in Ampd2m/m kidneys. A) Liver and kidney immunoblot analysis of Ampd2 protein in
B6 Ampd2+/+ and Ampd2m/m mice. C) Proteinaceous tubular casts were observed in the kidneys of Ampd2m/m mice. D) Interstitial nephritis was
observed in the kidneys of Ampd2m/m mice, but not in Ampd2+/+ mice (B). Bar = 100 μm.
















Figure 7 Electron micropscopic evaluation of the glomeruli from Ampd2m/m mice. Glomeruli of Ampd2m/m mice showed diffuse effacement,
sloughing, and fusing of podocyte foot processes (FP). Extensive blebbing, fusing, and surface pseudomembrane formation (PSM) was evident along
the glomerular tuft endothelium of Ampd2m/m mice (white arrowheads). In addition to a minimal to moderate thickening of the basal lamina (GBM),
there was a subtle increase in cellularity of the mesangial matrix (MM) and an increase in inflammatory cells, predominantly lymphocytes (LC) in
Ampd2m/m mice. RBC = Red Blood Cell. Upper photomicrographs 4200×; lower photomicrographs 6000×; Bar = 2 μm.
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type for the renal parameter (Figure 5). Conversely, pure
C3 Ampd2m/m mice showed no phenotype (data not
shown). Together, this suggests that the mixed background
can lead to a more severe phenotype, supporting the po-
tential presence of modifier alleles and their epistatic ef-
fects on lipid traits [16].
The renal phenotype in the B6 Ampd2m/m mice was
further characterized by TEM. The kidneys were col-
lected when lipid and renal phenotypes were most se-
vere. Consistent with the proteinuria observed in the
urine and proteinaceous tubular casts seen on histopath-
ology, Ampd2m/m mice were found to have damage to
the glomerular filtration membrane at the ultrastructural
level. Increases in inflammatory cells and in cellular deb-
ris also indicated progressive renal disease in Ampd2m/m
mice.
It is of interest to understand how the loss of Ampd2
function led to alterations in lipid profiles and kidney
function. Ampd plays roles both in the purine nucleotide
cycle as well as the catabolism of AMP to uric acid. In
the purine nucleotide cycle, three enzyme catalyzed re-
actions convert AMP to fumarate, in order to increase
the concentration of TCA cycle intermediates [17]. The
generation of fumarate provides skeletal tissue with its
only source of intermediate substrate for the TCA cycle[18] and loss of Ampd function reduces fumarate pro-
duction via the purine nucleotide cycle. This effect could
result in changes in the concentrations of malate, oxalo-
acetate, citrate, isocitrate, α-ketoglutarate and succinate
in the TCA cycle. Furthermore in the Ampd2m/m mice,
malate and citrate levels were elevated while succinate
levels were suppressed (Additional file 1: Table S1).
These alterations in TCA cycle intermediates are not
consistently decreased as could be expected by a defect-
ive purine nucleotide cycle by loss of Ampd2, suggesting
that this aspect of hepatic Ampd2 does not underpin the
lipid phenotype of the Ampd2m/m mice.
Ampd is also the rate limiting step in the degradation of
AMP [19], a defect in Ampd would be expected to lead to
an increase in AMP and a decrease in any intermediates
downstream of AMP, including IMP, inosine, hypoxanthine,
xanthine and uric acid. The metabolomic data showed sig-
nificant reduction in the downstream uric acid catabolic
intermediate, allantoin (Additional file 1: Table S1). If the
hepatic deficiency of Ampd2 is the primary cause of the
dyslipidemia, the defect in purine catabolism as here could
provide a pathogenic mechanism. Along these lines Yang
et al. [20] have reported that allantoin administration in
DIO mice significantly improved dyslipidemia. Metabolo-
mic analysis also demonstrated significant increases in
plasma plant sterols including campesterol and β-sitosterol.
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through hepatic biliary secretion using the ATP binding
cassette G5/8 (ABCG5/8) transporter complex. No gene
expression changes were observed for ABCG8 (Figure 3A)
suggesting the accumulation of β-sitosterol and campes-
terol were due to defects in posttranslational ABCG5/8
transporter function. Thus, one mechanism that may lead
to elevated plasma cholesterol observed in Ampd2m/m mice
may be defects in ABCG5/8 transporter function.
The presence of dyslipidemia together with kidney ab-
normalities would normally be indicative of NS as the
primary defect in the Ampd2m/m mice, as urinary pro-
tein loss is known to stimulate an increase in LDL syn-
thesis by the liver [21]. However, the Ampd2m/m mice do
not exhibit significantly elevated triglycerides (Figure 2C),
a hallmark of dyslipidemia secondary to NS due to im-
paired clearance of chylomicrons and VLDL [21]. Fur-
thermore induction of hypercholesterolemia during NS
is primarily related to upregulation of HMG-CoA reduc-
tase activity [22]. An upregulation of Hmgcr was not ob-
served in the liver of Ampd2m/m mice, and in fact, a
trend of decreased gene expression was observed
(Figure 3). Insulin-induced gene 1 (Insig1) was decreased
by 56% in Ampd2m/m mice, possibly resulting in less
binding of HMG CoA Reductase and increased choles-
terol biosynthesis. Transcript levels of 3-hydroxy-3-
methylglutaryl-CoA synthase (Hmgcs) were 47% lower in
Ampd2m/m mice, possibly due to feedback inhibition
caused by high levels of circulating plasma cholesterol,
albeit only a minimal reduction in Srebp1 and 2 was ob-
served. It has also been reported that rats with NS ac-
companied with hypercholesterolemia lack Cyp7a1
upregulation, while rats that have equally high hyper-
cholesterolemia due to a high fat diet do not present
with NS and show marked elevation of Cyp7a1 RNA
levels [22,23]. As shown in Figure 3, Ampd2m/m mice
demonstrated a modest but significantly increased ex-
pression of Cyp7a1 mRNA, consistent with the dietary
and not the NS induced lesion. This may be a compen-
satory mechanism to enhance cholesterol disposal
through bile acid synthesis and secretion and switching
to a different transporter in response to a defect in
ABCG5/8 function. Other discrepancies between NS
and dyslipidemia in Ampd2m/m mice and other rodent
NS models exist. Zhou et al. [24] as well as others
[25,26] have reported that Ldlr protein abundance is sig-
nificantly reduced in NS rats, with no concurrent reduc-
tion in Ldlr gene expression, whereas Ampd2m/m mice
showed significant reductions in both. Shearer et al. [27]
reported that in the nephrotic rat, proteinuria resulted
in reduced HDL ApoE content. We found increases in
both HDL-C and ApoE levels in our Ampd2m/m mice.
Liu and Vaziri [28] report that NS induced LDLR defi-
ciency is due to upregulation of PCSK9 and IDOL, bothpost-translational regulators of LDLR. We see no in-
creased expression of either gene in the Ampd2m/m
mice. Collectively, these data suggest that dyslipidemia is
a direct consequence of Ampd2 deficiency, and not a
consequence of NS. We propose that the pathogenic
mechanism relates to defective catabolism of AMP to
uric acid, including allantoin, versus impairment in the
purine nucleotide cycle.
Recently, Akizu et al. [29] reported an early onset neu-
rodegenerative condition resulting from mutations in
AMPD2 and found that AMPD2 plays a critical role in
the maintenance of guanine nucleotide pools in relation
to adenosine derivatives on de novo purine synthesis.
No neurological phenotypes were observed in Ampd2
knockout mice. Furthermore only Ampd2/3 double
knockout mice exhibited slightly reduced brain size, and
showed little evidence of the neuronal loss observed in
the AMPD2 mutant human population. Nucleotide ana-
lysis of the double knockout brains showed increases in
ATP nucleotide levels and a decrease in guanosine tri-
phosphate, consistent with the increased ATP found in
the liver of our Ampd2m/m mice. We also confirm a sig-
nificant reduction in levels of guanine in Ampd2m/m
mice; however our mice exhibited no obvious neuro-
logical phenotype.
In conclusion, we have identified a novel mouse model
of transient hypercholesterolemia with concurrent NS
associated with defective Ampd2 function. Ascertaining
whether the two phenotypes are interrelated and the
molecular mechanism of Ampd2 loss and hypercholes-
terolemia will require further investigation.
Materials and methods
Mouse breeding
Founder mice were identified at McLaughlin Research
Institute [11] and subsequent generations were main-
tained at Charles River Laboratories to generate mixed
C57BL/6 J (B6) C3.SW-H2b/SnJ (C3) animals. The
Ampd2 line was backcrossed to B6 via MAX-BAX® tech-
nology, and 2 of the 100% B6 congenic animals were ob-
tained for further heterozygous × heterozygous mating.
Mice were cared for in accordance to the Guide for the
Care and Use of Laboratory Animals, 8th Edition. Ani-
mals were single housed at an AAALAC accredited facil-
ity in non-sterile ventilated micro-isolator housing on
corn cob bedding. All research protocols were approved
by the (Amgen, Inc; Thousand Oaks) Institutional Ani-
mal Care and Use Committee. Animals had ad libitum
access to pelleted feed (diet 2020X, Harlan Teklad;
Indianapolis, IN) and water (reverse osmosis chlorinated
water) via automatic watering system. Animals were
maintained on a 12:12 hour light: dark cycle in rooms at
20–26°C, humidity maintained between 30-70% and had
access to enrichment opportunities.
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Blood samples were collected in EDTA plasma tubes via
the retro-orbital sinus of conscious mice. Plasma total chol-
esterol, HDL-cholesterol, triglyceride and albumin levels
were measured using the Olympus AU400e Chemistry
Analyzer (Olympus America, Inc; Center Valley, PA) from
plasma thawed on ice and diluted four-fold with saline.
ApoA1 and ApoE values were determined by immunoassay
(Linco Research; St. Charles, MO). Proteinuria was mea-
sured by dipping Albustix reagent strips directly into urine
(Siemens Medical; Malvern, PA).
Deoxycoformycin studies
Commercial deoxycoformycin (Pentostatin; Tocris Bio-
science; Bristol, UK) was dissolved in saline at a concen-
tration of 25 mg/mL. Subsequent dilutions were made
with saline and the mice were dosed via intraperitoneal in-
jections at a concentration of 10 mg/kg. Baseline plasma
samples were collected at 9 AM, immediately preceding a
single dose of deoxycoformycin, and terminal plasma sam-
ples were collected 24 hours later.
Quantitative RT-PCR analyses
Total liver RNA was isolated using an RNeasy Mini kit
(QIAGEN GmBH; Hilden, Germany) and A260 was mea-
sured using a Beckman Coulter DU 800 spectrophotom-
eter. RT-PCR reactions were set up using QuantiTect
Multiplex RT-PCR Kit (QIAGEN), and 100 ng RNA per
reaction was used, with appropriate oligonucleotides and
probes; Cyclophilin A used as the housekeeping gene
(sequences available upon request). Reactions were run
on an ABI Prism 7900HT temperature cycler (Life Tech-
nologies; Carlsbad, CA). Results were analyzed using
SDS2.2.2 software (Life Technologies).
Lipoprotein analysis by fast performance liquid
chromatography (FPLC)
Size-exclusion chromatography was performed by incorp-
orating two Superose 6 10/300 GL columns (Amersham
Biosciences; Piscataway, NJ) in tandem as described [30].
Fraction volumes of 275 μL were collected per well, from
which 80 μL was removed and mixed with 120 μL of re-
agent from a colorimetric Cholesterol E Kit (Wako Che-
micals USA; Inc., Richmond, VA) to measure cholesterol
levels. To ensure linearity, a standard curve of pure chol-
esterol was included for each sample plate.
Metabolomics
Mass spectrometry-based metabolite profiling analysis
was performed at Metanomics Health GmBH (Berlin,
Germany) on plasma and liver samples processed and ex-
tracted using a proprietary methods yielding a lipid and
polar fraction which were used for gas chromatography–
mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis, re-
spectively. For GC-MS analysis the samples were se-
quentially derivatized before measurement. For LC-MS/
MS analysis a proprietary technology was applied which
allows target and high sensitivity Multiple Reaction
Monitoring profiling in parallel to full screen analyses.
The method has been validated in separate experiments
to determine intra- and interday variability, blank por-
tions and linearity of each metabolite comprising
known and unknown signals. Thresholds for reliable
determination of the metabolite have been evaluated
and confirmed within the study. Liver metabolite data
were normalized to the dry weight of samples. For
plasma samples, this step was not necessary due to the
application of the same volume for each plasma sample.
Each metabolite was normalized against the median of
the data obtained from the control animals (ratios vs.
control). Two hundred and twenty four metabolites
were measured in plasma, 152 metabolites with known
structure. For liver samples, 574 metabolites were mea-
sured, 222 metabolites with known structure. Metabo-
lites with statistically significant differences between
genotypes are presented in Additional file 1: Table S1.High performance liquid chromatography (HPLC) analysis
of AMP, ADP, and ATP
Frozen (−80°C) mouse liver samples were homogenized
at 10% (w/v) in acetonitrile, 10 mM KH2PO4 buffer
pH 7.4 (3:1). The homogenate was centrifuged at
20,000 × g, 4°C, for 10 minutes and the supernatant cen-
trifuged again at 20,000 × g, 4°C, for 10 minutes. The
acetonitrile was removed by chloroform extraction three
times. Final aqueous layer extract was diluted with
10 mM KH2PO4 Buffer, pH 7.4 to initial volume. Sam-
ples (20 μL) were analyzed using an Agilent 1100 Series
HPLC equipped with a Hypersil Gold C-18, 250 ×
4.6 mm 5 μm particle size HPLC column at a flow rate
of 0.75 mL/minute using a 130 min step gradient proto-
col as follows: 10 minutes (100% A-10 mM tetrabuty-
lammonium hydroxide, 10 mM KH2PO4, 0.125%
methanol, pH 7.0), 3 minutes (80% A: 20% B- 2.8 mM
tetrabutylammonium hydroxide, 100 mM KH2PO4, 30%
methanol, pH 5.5), 10 minutes (70% A: 30% B), 12 mi-
nutes (55% Line A: 45% B), 11 minutes (40% A: 60% B),
9 minutes (35% A: 56% B), 10 minutes (25% A: 75% B),
30 minutes (100% B), 36 minutes (100% A). Spectra were
collected at 206 nm and 260 nm for AMP (29.4 Reten-
tion Time), ADP (41.4 Retention Time), and ATP (49.1
Retention Time). Data was processed using Agilent
Chemstation software using a standard curve for each
analyte. The precision (%CV) of the assay was very good:
3.9% for AMP, 6.3% for ADP, and 3.9% for ATP with a
limit of quantification of 0.1 μmol/g liver tissue.
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PCR DNA fragments of candidate genes were subcloned
into the pCR II vector using a TA cloning kit and se-
quenced with M13F and M13R primers or directly
sequenced with the PCR primers on an ABI 3730xl DNA
Analyzer. To genotype the guanine to thymine transver-
sion of Ampd2, a BseR1 restriction digest was applied to a




Approximately 20–40 mg of frozen liver or kidney were ho-
mogenized in NP40 lysis buffer with 1X of Complete Prote-
ase Inhibitors Cocktail (Roche; Indianapolis, IN). Protein
lysates were resolved on 4-12% Bis-Tris polyacrylamide gels
(Life Technologies). Separated proteins were transferred to
PVDF membranes (Life Technologies), and blocked with
Pierce Superblock. The blots were hybridized with anti-
bodies directed against Ampd2 (QQ13; Santa Cruz Bio-
technology, Inc. Dallas, TX), Ldlr (Cayman Chemical; Ann
Arbor, MI), Gapdh (IMGENEX; San Diego, CA) or β-actin
(Sigma-Aldrich) overnight at 4°C with gentle shaking. The
membranes were washed 3 times with TBS-T, incubated
with secondary antibody conjugated to HRP at room
temperature for 1.5 hours, and washed another 3 times in
large volume changes of TBS-T. The blots were processed
with SuperSignal West Dura substrate (Thermo Fisher Sci-
entific, Inc. Rockford, IL), and visualized on a Fluorochem
HD2 imager (ProteinSimple, Santa Clara, California).
Histological analysis
Samples of kidney were fixed by immersion in 10% neu-
tral buffered formalin for 24 hours, trimmed into cas-
settes, processed routinely to paraffin embedment,
sectioned at 5 μm, stained with hematoxylin and eosin
and periodic acid methenamine silver [31] and examined
histologically.
Electron microscopy
A portion of the renal cortex was collected for transmis-
sion electron microscopy (TEM), minced into 1 mm
cubes and placed into 2.5% glutaraldehyde fixative. Fol-
lowing fixation, the tissues were processed for TEM.
Samples were first rinsed in 0.1 M Sorenson’s Phosphate
buffer, post-fixed in 2% osmium tetroxide, embloc
stained with uranyl acetate, after which the tissues were
dehydrated through a graded series of alcohol and acet-
one then 100% Spurr’s resin and cured at 65°C. Semi-
thin sections (500 nm sections stained with Toluene
blue) of each resin block were examined and four resin
blocks/animal were chosen for thin sectioning (80–
90 nm, gold sections placed on a 100 μm mesh copper
grid). The four grids per animal were examined on botha JEM 100 kV (JEOL USA; Inc. Peabody, MA) and a
Tecnai 110 kV (TEI; Hillsboro, OR) microscope with ten
digital photomicrographs shot for each resin block
thereby providing an adequate number of photomicro-
graphs for comparison between the genotypes.
Statistical analysis
In some graphs individual mouse values are shown with
means ± SEM. In other graphs only the means ± SEM are
displayed. Statistical analyses were carried out by one-way
ANOVA using a Tukey post test comparing with three or
more groups. For statistical analyses comparing two
groups unpaired two-tailed t-tests for used; * p <0.05;
** p <0.01; *** p <0.001; **** p <0.0001 vs. Ampd2+/+.
Additional files
Additional file 1: Table S1. Metabolomic analysis of significantly
altered metabolites in liver and plasma in Ampd2m/m and Ampd2+/+ mice.
Values represent the fold change. Statistical analyses were carried out by
unpaired two-tailed t-tests.
Additional file 2: Figure S1. Effects of deoxycoformycin, a potent
inhibitor of AMPD/adenosine deaminase in B6 mice. Cholesterol (A) as
well as urinary protein levels (B) were elevated 24 hours post injection.
Statistical analyses were carried out by unpaired two-tailed t-tests;
* p <0.05 ***; p <0.001 vs. saline.
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